stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) EPS (diluted)
Genmab A/S Sponsored ADR's EPS (diluted) for fiscal 2025 was $1.54, down 12.5% from $1.76 in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.27. Over the past ten years it has ranged from $0.27 (fiscal 2016) to $1.76 (fiscal 2024); the current reading is higher than 90% of that period. Genmab A/S Sponsored ADR ranks 35th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.54 | (12.50%) |
| FY2024 | $1.76 | 83.33% |
| FY2023 | $0.96 | (16.52%) |
| FY2022 | $1.15 | 59.72% |
| FY2021 | $0.72 | (35.71%) |
| FY2020 | $1.12 | 119.61% |
| FY2019 | $0.51 | 35.67% |
| FY2018 | $0.38 | 33.01% |
| FY2017 | $0.28 | 4.74% |
| FY2016 | $0.27 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.49 | 512.50% |
| Mar 2026 | $0.08 | 60.00% |
| Dec 2025 | $0.05 | (92.31%) |
| Sep 2025 | $0.65 | 20.37% |
| 27 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $19.26 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| INCY Incyte Corporation compare | $1.88 |
| RPRX Royalty Pharma PLC compare | $1.40 |
| GMAB Genmab A/S Sponsored ADR | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| INSM Insmed, Inc. compare | −$2.82 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
| RVMD Revolution Medicines, Inc. compare | −$9.11 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GMAB
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement